AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 188 filers reported holding AKERO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,921,434 | +9.5% | 97,300 | +1.0% | 0.00% | +33.3% |
| Q2 2023 | $4,496,247 | +79.1% | 96,300 | +46.8% | 0.00% | +50.0% |
| Q1 2023 | $2,509,856 | -35.5% | 65,600 | -7.6% | 0.00% | -33.3% |
| Q4 2022 | $3,890,800 | +65.1% | 71,000 | +2.6% | 0.00% | +50.0% |
| Q3 2022 | $2,356,000 | +404.5% | 69,200 | +40.1% | 0.00% | – |
| Q2 2022 | $467,000 | -11.2% | 49,400 | +33.2% | 0.00% | – |
| Q1 2022 | $526,000 | -27.7% | 37,100 | +7.8% | 0.00% | – |
| Q4 2021 | $728,000 | -5.3% | 34,400 | 0.0% | 0.00% | – |
| Q3 2021 | $769,000 | -9.8% | 34,400 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $853,000 | -16.7% | 34,400 | -2.5% | 0.00% | 0.0% |
| Q1 2021 | $1,024,000 | +12.4% | 35,300 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $911,000 | -14.5% | 35,300 | +2.0% | 0.00% | 0.0% |
| Q3 2020 | $1,065,000 | +90.9% | 34,600 | +54.5% | 0.00% | – |
| Q2 2020 | $558,000 | – | 22,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $125,180,178 | 50.58% |
| COMMODORE CAPITAL LP | 790,000 | $30,225,400 | 4.60% |
| Redmile Group, LLC | 2,044,389 | $78,218,323 | 3.39% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 202,561 | $7,749,984 | 3.20% |
| Ghost Tree Capital, LLC | 275,000 | $10,522,000 | 3.11% |
| Avidity Partners Management LP | 2,447,000 | $93,622,220 | 3.11% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $22,736,043 | 3.08% |
| Logos Global Management LP | 400,000 | $15,304,000 | 2.19% |
| Yiheng Capital Management, L.P. | 1,125,791 | $43,072,764 | 1.70% |
| Boxer Capital, LLC | 831,495 | $31,813 | 1.56% |